Alexion Pharma Receives European Approval for Ultomiris
Alexion Pharmaceuticals (ALXN) announced that its lead drug candidate Ultomiris has been approved by the European Commission. Ultomiris may now be used for treating adults and children with atypical hemolytic uremic syndrome in Europe. The drug candidate is the first and only long-acting C5 complement inhibitor that needs to be administered every eight weeks.
The European Commission based its data on two global, single arm studies of the drug candidate. One of these studies was conducted in adults while the other was conducted in children. Both